使用ProMise分类器对子宫内膜癌患者的分析:来自印度的试点研究
Alka Dahiya1, Abarna Rajadurai2, Sherin Daniel2
1Department of Gynaecological Oncology, Christian Medical College, Vellore, Tamil Nadu, 632004, India.
Archives of gynecology and obstetrics
|September 14, 2023
概括
使用POLE,p53突变和不匹配修复 (MMR) 状态对子宫内膜癌 (EC) 的分子亚型提供预后见解. 具有POLE突变的瘤显示出最好的预后,而p53突变显示出最糟糕的结果.
科学领域:
- 在瘤学瘤学.
- 分子病理学分子病理学
- 癌症基因组学 癌症基因组学
背景情况:
- 子宫内膜癌 (EC) 的分子亚型化有助于预后.
- 像POLE突变,p53突变和不匹配修复 (MMR) 状态这样的有限分子标记可以提供有价值的EC特征.
研究的目的:
- 使用关键分子标记物来表征子宫内膜癌.
- 分析这些分子亚型与患者生存的预后相关性.
主要方法:
- 分析了来自48名EC患者的甲胺固定嵌组织.
- 通过桑格测序评估POLE突变;通过免疫组织化学 (IHC) 评估MMR状态和p53拷贝数.
- 临床病理学数据和生存分析与突变状态相结合.
主要成果:
- 在22.9%的病例中发现了MMR缺乏,在6.3%的病例中发现了POLE突变,在25%的病例中发现了p53突变.
- 波尔突变瘤的预后最好,而p53突变和多个分类器组的预后最差.
- 总生存率 (OS) 和无进展生存率 (PFS) 显示出基于分子谱的显著差异 (Log-rank p:0.006对于OS,p:0.001对于PFS).
结论:
- 通过成本有效的测试整合分子和临床病理学数据是EC分类的客观工具.
- 这种方法可以在资源有限的环境中采用,并可能改变EC病理和管理范式.
更多相关视频
07:46Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells
Published on: October 13, 2023
1.3K
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
6.8K
相关概念视频
Cancer Survival Analysis
381
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
381
Kaplan-Meier Approach
178
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
178
